Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – Still a Buy?

by · The Markets Daily

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Get Free Report)’s stock price gapped up before the market opened on Friday . The stock had previously closed at $62.45, but opened at $66.03. Structure Therapeutics shares last traded at $66.6750, with a volume of 204,678 shares.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on GPCR shares. Jefferies Financial Group set a $125.00 price objective on Structure Therapeutics and gave the company a “buy” rating in a report on Thursday, December 11th. Lifesci Capital upgraded shares of Structure Therapeutics to a “strong-buy” rating in a research note on Monday, September 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Wednesday, October 8th. Piper Sandler reissued an “overweight” rating on shares of Structure Therapeutics in a research note on Tuesday, October 28th. Finally, Morgan Stanley lifted their price target on shares of Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Structure Therapeutics has an average rating of “Moderate Buy” and an average price target of $99.11.

View Our Latest Stock Analysis on GPCR

Structure Therapeutics Price Performance

The firm’s 50 day moving average price is $38.18 and its two-hundred day moving average price is $26.90. The firm has a market cap of $4.17 billion, a price-to-earnings ratio of -56.54 and a beta of -1.64.

Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last released its earnings results on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.01). On average, analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. State of Wyoming purchased a new position in Structure Therapeutics during the 2nd quarter valued at about $28,000. EverSource Wealth Advisors LLC grew its position in shares of Structure Therapeutics by 530.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after purchasing an additional 901 shares during the last quarter. Assetmark Inc. grew its position in shares of Structure Therapeutics by 39.9% in the second quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after purchasing an additional 820 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Structure Therapeutics by 29.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock worth $92,000 after purchasing an additional 994 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd raised its position in shares of Structure Therapeutics by 39.1% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock worth $114,000 after purchasing an additional 1,146 shares during the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

About Structure Therapeutics

(Get Free Report)

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

Recommended Stories